Clinical trials: Bone Marrow
Amyotrophic Lateral Sclerosis, ALS
Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the safety and efficacy of autologous bone marrow-derived stem cells("HYNR-CS inj"), through intrathecal delivery for the treatment in patients with ALS. This study consists of 2 steps.
- Trial name
- NCT01363401
- Testing
- HYNR-CS inj, Control group
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Corestemchemon, Inc.
MDS
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)
This study is designed as a multicenter trial, with biological assignment to one of two study arms; Arm 1: Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT), Arm 2: Non-Transplant…
- Trial name
- NCT02016781
- Testing
- Allogeneic Hematopoietic Cell Transplant, Hypomethylating Therapy / Best Supportive Care
- Where
- 37 sites in United States
- Volunteers
- 384 people
- Sponsor
- Medical College of Wisconsin
Osteoarthritis
Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES)
The study is a multicenter trial conducted to compare the effectiveness of an injection of a corticosteroid control to mesenchymal stem cell (MSC) preparations from autologous bone marrow concentrate (BMAC), adipose derived stem…
- Trial name
- MILES (NCT03818737)
- Testing
- Bone Marrow Derived MSCs, Adipose-derived MSCs, Umbilical Cord Tissue (UCT) MSCs
- Where
- 5 sites in United States
- Volunteers
- 475 people
- Sponsor
- Emory University
Polycythemia Vera
A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)
This study will evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics of the orally administered lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat, in participants with polycythemia vera (PV).
- Trial name
- NCT05558696
- Testing
- Bomedemstat
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 20 people
- Sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Current protocols use G-CSF to mobilize hematopoietic progenitor cells from matched sibling and volunteer unrelated donors. Unfortunately, this process requires four to six days of G-CSF injection and can be associated with side…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma
- Trial name
- NCT02639559
- Testing
- BL-8040, Leukapheresis, Hematopoietic cell transplant
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Change in Bone Mineral Density, Change in Bone Marrow Fat Content
The Effect of Glitazone Treatment on Bone Marrow and Bone Marrow Cells
Osteoporosis is a generalised bone disease leading to an increased risk of fractures. The disease is caused partly by environmental and partly by genetic factors.
- Trial name
- NCT00609362
- Testing
- Rosiglitazone
- Where
- Denmark
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Chronic Phase Chronic Myeloid Leukemia
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
The study purpose is to test the hypothesis that Chronic Phase Chronic Myeloid Leukemia (CP-CML) patients with stable Complete Molecular Response (CMR) who discontinue Dasatinib treatment are able to maintain a sustained…
- Trial name
- DASFREE (NCT01850004)
- Testing
- Dasatinib
- Where
- 28 sites in United States, Canada and 4 more
- Volunteers
- 84 people
- Sponsor
- Bristol-Myers Squibb
Myelofibrosis
INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.
The primary objective of this study was to collect additional safety of INC424 in patients with Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis, who either received prior…
- Trial name
- JUMP (NCT01493414)
- Testing
- INC424
- Where
- 273 sites in Algeria, Argentina and 23 more
- Volunteers
- 2,233 people
- Sponsor
- Novartis Pharmaceuticals
Graft Versus Host Disease, Leukemia
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can find cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00555048
- Testing
- alemtuzumab, busulfan, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Fred Hutchinson Cancer Center
Paroxysmal Nocturnal Hemoglobinuria
Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
The primary objective of this study is to evaluate pharmacokinetics (PK) of ravulizumab administered subcutaneously via an on-body delivery system (OBDS) compared with intravenously administered ravulizumab in adult participants…
- Trial name
- NCT03748823
- Testing
- Ravulizumab OBDS, Ravulizumab
- Where
- 51 sites in United States, Australia and 12 more
- Volunteers
- 139 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hematological Malignancies
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
The purpose of this research study is to find out more information relating to the highest dose of KCP-330 that can be given safely and side effects it may cause, to examine how the body affects KCP-330 concentrations in the…
- Trial name
- NCT01607892
- Testing
- KPT-330
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 286 people
- Sponsor
- Karyopharm Therapeutics Inc
Influenza
Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza
This is a randomized, double-blind, placebo-controlled pilot study of the efficacy and safety of baloxavir in combination with oseltamivir (standard of care) for the treatment of influenza in allogeneic stem cell transplant…
- Trial name
- NCT05170009
- Testing
- Baloxavir Marboxil, Oseltamivir
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Weill Medical College of Cornell University
Chronic Lymphocytic Leukemia
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
Background: Combined therapy with rituximab and fludarabine is the treatment of choice for advanced stage chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
- Trial name
- NCT00001586
- Testing
- Rituximab, Fludarabine phosphate, Leukemic or stroma cells
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, 17p Deletion
A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion
This was an open-label, multicenter, global study to determine the efficacy of ABT-199 (Venetoclax) monotherapy in participants with relapsed/refractory (R/R) or previously untreated chronic lymphocytic leukemia (CLL) harboring…
- Conditions
- Chronic Lymphocytic Leukemia, 17p Deletion, Cancer of the Blood and Bone Marrow
- Trial name
- NCT01889186
- Testing
- ABT-199 (Main Cohort), ABT-199 (Safety Expansion Cohort)
- Where
- 48 sites in United States, Australia and 5 more
- Volunteers
- 158 people
- Sponsor
- AbbVie
Myeloid Leukemia, Chronic, Chronic Phase
Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses
The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participants with CP-CML who are resistant to prior tyrosine-kinase inhibitor (TKI)…
- Trial name
- OPTIC (NCT02467270)
- Testing
- Ponatinib
- Where
- 86 sites in United States, Argentina and 19 more
- Volunteers
- 283 people
- Sponsor
- Takeda
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
This clinical trial is studying how well giving fludarabine phosphate and melphalan together with total-body irradiation followed by donor stem cell transplant works in treating patients with hematologic cancer or bone marrow…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00856388
- Testing
- fludarabine phosphate, melphalan, total-body irradiation
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to compare the effects, good and/or bad, of a standard chemotherapy regimen for AML that includes the drugs daunorubicin and cytarabine combined with or without midostaurin (also known as PKC412), to…
- Trial name
- NCT00651261
- Testing
- cytarabine, daunorubicin, midostaurin
- Where
- 176 sites in United States, Canada
- Volunteers
- 717 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chronic Myeloid Leukemia
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
Two-arm, randomized, open-label trial designed to evaluate the efficacy and safety of bosutinib alone compared to imatinib alone in subjects newly diagnosed with chronic phase Chronic Myelogenous Leukemia (CML).
- Trial name
- NCT00574873
- Testing
- Bosutinib, imatinib
- Where
- 165 sites in United States, Argentina and 27 more
- Volunteers
- 502 people
- Sponsor
- Pfizer
Myelodysplastic Syndromes
To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.
The purpose of this study is to compare the response of patients with Intermediate or High Risk myelodysplastic syndromes (MDS) following treatment with decitabine or azacitidine.
- Trial name
- NCT01011283
- Testing
- decitabine, azacitidine
- Where
- 19 sites in United States
- Volunteers
- 26 people
- Sponsor
- Eisai Inc.
Polycythemia Vera, Thrombocythemia
Pomalidomide for Myelofibrosis Patients
The goal of this clinical research study is to learn if CC-4047 (now called pomalidomide) and prednisone can help to control MMM. The safety of this therapy will also be studied.
- Trial name
- NCT00946270
- Testing
- CC-4047, Prednisone
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.